# A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

> **NCT06963710** · PHASE2 · RECRUITING · sponsor: **Aligos Therapeutics** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis B Infection

## Interventions

- **DRUG:** ALG-000184
- **DRUG:** TDF

## Key facts

- **NCT ID:** NCT06963710
- **Lead sponsor:** Aligos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-03
- **Final completion:** 2028-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963710, "A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06963710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*